Related Experiment Video
Updated: Mar 21, 2026
Methods for Studying Uterine Contributions to Pregnancy Establishment in an Ovariectomized Mouse Model
Published on: April 7, 2023
Technical Update No. 467: Progesterone for Previous Spontaneous Preterm Birth
Venu Jain1, Sarah D McDonald2, Dan Farine3
1Edmonton, AB.
Objective:
To assess the benefits and risks of progesterone therapy for women at increased risk of spontaneous preterm birth and to make recommendations for the use of progesterone to reduce the risk of spontaneous preterm birth and improve postnatal outcomes.
Target Population:
Pregnant women at increased risk of spontaneous preterm birth (SPB) solely because of prior spontaneous preterm birth.
Options:
To administer or withhold progesterone therapy for women deemed to be at high risk of SPB.
Outcomes:
Preterm birth, neonatal morbidity and mortality, and postnatal outcomes including neurodevelopmental outcomes.
Benefits, Harms, And Costs:
Therapy with progesterone significantly reduces the risk of spontaneous preterm birth only in some subpopulations of women at increased risk. Although this therapy entails a cost to the woman in addition to the discomfort associated with its use, no other significant adverse effects to the mother or the newborn have been identified.
Evidence:
Medline, PubMed, EMBASE, and the Cochrane Library were searched from November 2018 to November 2025 for medical subject heading (MeSH) terms and keywords related to pregnancy, preterm birth, previous preterm birth, neonatal morbidity and mortality, and postnatal outcomes. This document represents an abstraction of the evidence rather than a methodological review.
Validation Methods:
The authors rated the quality of evidence and strength of recommendations using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. See online Appendix A (Tables A1 for definitions and A2 for interpretations).
Intended Audience:
Obstetric care providers, including obstetricians, family physicians, nurses, midwives and maternal-fetal medicine specialists SOCIAL MEDIA ABSTRACT: Progesterone therapy should be used in women with a short cervix on transvaginal imaging (≤25 mm) in the current pregnancy (between 16-24 weeks) but not in those with a history of spontaneous preterm birth and a normal cervical length.
Summary Statements:
RECOMMENDED CHANGES IN PRACTICE: RECOMMENDATIONS.
More Related Videos
14:43A Novel Method for Involving Women of Color at High Risk for Preterm Birth in Research Priority Setting
Published on: January 12, 2018
12:02Human Primary Trophoblast Cell Culture Model to Study the Protective Effects of Melatonin Against Hypoxia/reoxygenation-induced Disruption
Published on: July 30, 2016
Related Concept Videos
01:21Intrauterine Drug Delivery Systems
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
01:07Teratogenicity
01:24Gonadal and Placental Hormones
In males, testosterone is the primary gonadal androgen. It plays a central role in the maturation of male reproductive organs — the penis and testes. Additionally, testosterone is instrumental in the development of secondary sexual characteristics — a deep voice as well as facial and pubic hair...
01:22Birth Control Methods
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...